Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Lymphoma, B-Cell
Clinical trial register · United States · industry-sponsored

Lymphoma, B-Cell Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9183 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 02 Nov 2026, 03:16 UTC
9183
Studies in scope
industry-sponsored, all four open statuses
4981
Recruiting now
open to new participants
2200
Lead sponsors
across recruiting studies
Top states
California 7 Arizona 4 Colorado 4 Florida 4 Georgia 3
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Lymphoma, B-Cell trials in the USA

10 of 9183 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
NCT07735533Lymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma, Richter Transformation Lymphoma
Umoja Biopharma
Phase 1/2
274
Tennessee
2026-09
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Lyell Immunopharma, Inc.
Phase 3
400
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-01-12
Recruiting
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06528301Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
Umoja Biopharma
Phase 1
106
California, Illinois, Michigan, Missouri, Nebraska, Ohio, Washington
2025-03-10
Recruiting
Bantam Pharmaceuticals
Phase 1
24
North Carolina, Texas
2025-02-14
Active, closed
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC
Phase 1/2
166
California, Colorado, Iowa, Kentucky, New Jersey, North Carolina, Ohio, Pennsylvania
2022-08-12
Recruiting
Step Pharma, SAS
Phase 1/2
180
Colorado, Florida, New York
2022-08-03
Active, closed
Celgene
Phase 1
224
Alabama, Arizona, California, Florida, Georgia, Kansas, Minnesota, Nebraska
2021-09-15
Active, closed
FT819 in Subjects With B-cell Malignancies
NCT04629729Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
Fate Therapeutics
Phase 1
54
Alabama, Arizona, California, Florida, Iowa, Kansas, Kentucky, Minnesota
2021-07-12
Active, closed
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
NCT03162536Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2
190
Arizona, California, Colorado, Michigan, Minnesota, North Carolina, Ohio, Tennessee
2017-06-26
Active, closed
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease
Pharmacyclics Switzerland GmbH
Phase 4
297
California, Georgia, Illinois, Kentucky, Massachusetts, Michigan, Nevada, New Jersey
2017-05-22
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 3 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/lymphoma-b-cell

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,183 studies in total at the last sync on 02 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition Lymphoma, B-Cell.

How many Lymphoma, B-Cell trials are recruiting in the US?

5 of the 10 studies on this page are recruiting new participants as of the 02 Nov 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lymphoma, B-Cell), 10 studies
PhaseStudiesRecruitingShare
Phase 14240%
Phase 1/24240%
Phase 31110%
Phase 41010%

Most active sponsors

Lead sponsors with the most studies (Lymphoma, B-Cell)
Lead sponsorStudiesRecruiting
Umoja Biopharma22
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)10
Bantam Pharmaceuticals11
Celgene10
Fate Therapeutics10
Janssen Research & Development, LLC10
Lyell Immunopharma, Inc.11
Pharmacyclics Switzerland GmbH10
Step Pharma, SAS11

Top states

Top states (Lymphoma, B-Cell), by number of studies with a site there
StateStudies
California7
Arizona4
Colorado4
Florida4
Georgia3
Illinois3
Kentucky3
Michigan3
Minnesota3
North Carolina3
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.